Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia.

To evaluate the treatment of endometrial hyperplasia (EH) with different progestins.
Eighty-two women with simple EH without atypia were included. Patients were offered oral progestagens and were randomized to one of three options for 3 months: medroxyprogesterone acetate (MPA, 10 mg/day), lynestrenol (LYN, 15 mg/day) and norethisterone (NET, 15 mg/day) for 10 days per cycle. Patients were reevaluated after treatment. Women diagnosed with proliferative and nonatypical EH at the second curettage were offered the same progestins for another 3 months. The primary outcome of the study was the proportion of women requiring further treatment.
Of the 82 women, 46 (56.1%) received MPA (23.2%), LYN (13.4%) and NET (19.5%) therapy for another 3 months at the end of the first 3 months of treatment. The patients receiving MPA showed resolution in 36.7% of the cases versus 37% in the NET group. The highest resolution rate (56%) was observed in the LYN group, although there was no statistically significant difference between progestins regarding the proportion of women requiring further treatment (χ(2) = 2.608; p = 0.271).
It seems that the efficacies of oral progestins are similar at these dosages in simple EH without atypia.
AuthorsOzlem Ozdegirmenci, Fulya Kayikcioglu, Ulku Bozkurt, Mehmet Akif Akgul, Ali Haberal
JournalGynecologic and obstetric investigation (Gynecol Obstet Invest) Vol. 72 Issue 1 Pg. 10-4 ( 2011) ISSN: 1423-002X [Electronic] Switzerland
PMID21266792 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
CopyrightCopyright © 2011 S. Karger AG, Basel.
Chemical References
  • Progestins
  • Medroxyprogesterone Acetate
  • Lynestrenol
  • Norethindrone
  • Adult
  • Endometrial Hyperplasia (drug therapy)
  • Female
  • Humans
  • Lynestrenol (administration & dosage)
  • Medroxyprogesterone Acetate (administration & dosage)
  • Middle Aged
  • Norethindrone (administration & dosage)
  • Progestins (administration & dosage)
  • Prospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: